ACI HealthCare Limited (AHL) was established on February 18, 2013, as a specialized public limited subsidiary of Advanced Chemical Industries (ACI) PLC, carrying forward a heritage that originated in 1973 when the organization operated as Imperial Chemical Industries (ICI PLC) Bangladesh. With this legacy, ACI HealthCare Limited (AHL) was formed with a clear purpose , to elevate Bangladesh’s pharmaceutical manufacturing capability to meet the standards of the world’s most stringent and regulated markets.
Our strategic mandate is centered on regulated-market manufacturing and global healthcare access, with particular focus on regions such as the United States, Europe, and other advanced international markets. This direction demands uncompromising quality, disciplined operational governance, and alignment with global regulatory bodies, including the US FDA and other internationally recognized authorities.
ACI HealthCare Limited (AHL)’s mission is to achieve business excellence through quality by planning, implementing, controlling and improving the standards of its products & services for exceeding customer expectations on continuous basis.
ACI HealthCare Limited (AHL)’s vision is to play a leading role in improving the quality of life and well-being of the people through responsible application of knowledge and skills.
Contrary to popular belief, from 45 BC, making it over 2000 years old.
Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
First Bangladeshi pharma plant to receive US FDA approval on Year 2022
First Bangladeshi pharma plant to receive US FDA approval on Year 2022
First Bangladeshi pharma plant to receive US FDA approval on Year 2022
First Bangladeshi pharma plant to receive US FDA approval on Year 2022
First Bangladeshi pharma plant to receive US FDA approval on Year 2022
Donec lobortis dui eu elit feugiat, eu sagittis ante elementum. Mauris accumsan arcu sed odio dictum aliquet. Donec at imperdiet nunc, id cursus risus. Pellentesque molestie mi vitae risus pretium, maximus aliquet orci tincidunt. Aenean volutpat diam at risus blandit.
Donec lobortis dui eu elit feugiat, eu sagittis ante elementum. Mauris accumsan arcu sed odio dictum aliquet. Donec at imperdiet nunc, id cursus risus. Pellentesque molestie mi vitae risus pretium. Donec at imperdiet nunc,
Donec lobortis dui eu elit feugiat, eu sagittis ante elementum. Mauris accumsan arcu sed odio dictum aliquet.
Lorem ipsum dolor sit amet consectetur. Nunc faucibus quam dis pharetra egestas in sapien augue dis. Volutpat nisi aliquet eros sagittis nisl cras nunc non integer.